24.7 C
Vientiane
Wednesday, October 8, 2025
spot_img
Home Blog Page 449

METABORA GAMES and Baligames to Participate in ‘WebX 2025’ and Showcase New Title ‘Puzzle & Guardians’

  • Core partner of LINE NEXT and Kaia DLT Foundation’s “Mini Dapp Station” at Japan’s largest Web3 conference
  • Unveiling a new hybrid genre that combines casual match-3 puzzles with RPG growth mechanics
  • Launch of teaser page for new product brand “BORA DEEPS” to strengthen user engagement within the BORA ecosystem

SEOUL, South Korea, Aug. 25, 2025 /PRNewswire/ — METABORA GAMES (CEO Choi Se-hoon), a leading blockchain game developer, announced today that it has unveiled its upcoming title ‘Puzzle & Guardians’ in partnership with Baligames (CEO Kim Young-woo) at WebX 2025, Japan’s largest Web3 event.

METABORA GAMES and Baligames to Participate in  ‘WebX 2025’ and Showcase New Title ‘Puzzle & Guardians'
METABORA GAMES and Baligames to Participate in ‘WebX 2025’ and Showcase New Title ‘Puzzle & Guardians’

The two companies are participating as core partners of the Mini Dapp Station, co-hosted by LINE NEXT and the Kaia DLT Foundation, where they are showcasing gameplay videos, offering on-site demo opportunities, and engaging with global users until August 26.

‘Puzzle & Guardians’ is the first LINE Messenger-based mini Dapp game developed through the partnership between the two companies. The hybrid title combines the casual fun of a match-3 puzzle with RPG growth elements, incorporating with Web3 reward mechanisms to deliver a distinctive gameplay experience.

The co-launch partner, Baligames, is a rising Korean game studio founded by core developers behind global hits like the Anipang series. The studio, with extensive experience in mobile game development and live operations, became the first in Korea to secure strategic investment from Sky Mavis, the creators of Axie Infinity, a leading title in the global Web3 game space.

In addition, METABORA GAMES unveiled the teaser page for its new product brand, ‘BORA DEEPS’, at the event. Positioned as a key infrastructure to strengthen user engagement within the BORA ecosystem, ‘BORA DEEPS’ will gradually roll out a variety of services designed to create synergy between content and users.

As its first service, ‘QUEST’, a reward platform that integrates in-game missions with Web3 incentive systems, will be applied to Puzzle & Guardians and officially launched in line with the game’s release.

A METABORA GAMES representative commented, “We are delighted to showcase our upcoming Web3 game, developed in collaboration with a promising partner, to global users through participation in this prestigious global Web3 event. We will continue to strengthen our position as a core partner in producing and distributing competitive Web3 titles within the Dapp Portal, while gradually expanding our game lineup and enhancing the BORA tokenomics.”

About METABORA GAMES

METABORA GAMES is a leading blockchain game developer and the operator of the blockchain platform BORA. With its roots in casual game development and blockchain expertise, the company is driving innovation where Web2 and Web3 entertainment converge.

BORA is a next-level on-chain platform designed to enhance player engagement and experiences. The BORA ecosystem brings together partners across tokenomics, content, and blockchain technology, fostering collaboration throughout gaming, entertainment, and sports.

Through the BORA Network, METABORA operates the BORA Portal, which offers GameFi-optimized services such as NFT trading, token conversion, and DeFi features. With BORA listed on major global cryptocurrency exchanges, METABORA continues to enhance accessibility and expand the usability of its content across the Web3 landscape.

#Appendix
BORA DEEPS teaser page: https://intro.boradeeps.com/intro

Blitz Electric Mobility, Indonesia’s Leading EV Logistic Enabler, secures Pre-Series A Investment Led by Vynn Capital

KUALA LUMPUR, Malaysia, Aug. 25, 2025 /PRNewswire/ — Blitz Electric Mobility (Blitz), Indonesia’s leading EV logistics enabler, has closed a Pre-Series A funding round led by Malaysia-based Vynn Capital. 

Blitz Founding Team (from left to right): William So (CFO), Saivya Chauhan (CEO), Charles (COO)
Blitz Founding Team (from left to right): William So (CFO), Saivya Chauhan (CEO), Charles (COO)

This investment marks Vynn Capital’s ongoing commitment through its mobility and supply chain fund, with participation from existing Blitz investor Iterative Capital. The round also brings in notable new backers, including former Andreessen Horowitz general partner Balaji Srinivasan, ex‑PayPal exec Rajesh Venkatesh, and Vinner Ventures. These add to Blitz’s roster of impact-driven institutional investors such as Asian Development Bank (ADB) Ventures, FiveFortyAlpha, BonBillo Fund, and Peak XV.

A Business Model Built for Scale and Sustainability 

Blitz’s asset-light, tech-first approach places it at the forefront of sustainable logistics in Indonesia’s last-mile delivery market. The company addresses three critical challenges: meeting instant delivery demands, overcoming the complexities of scaling in-house logistics, and enabling cleaner, electrified infrastructure. Blitz empowers businesses with scalable, same-day, and instant delivery without the need to own or manage their own fleet assets. 

Blitz operates a growing pool of thousands of gig couriers, providing tailored B2B logistics solutions that include: 

  • 1- to 12-hour instant and same-day deliveries
  • Integrated white-label logistics services
  • Comprehensive delivery management under clients’ own brands 

Unlike other players, Blitz has built a unique model designed for sustainable margins, long-term client partnerships, and embedded EV financing for gig workers. 

In 2024, Blitz had tripled its revenue while cutting its burn rate by over 70%, significantly optimising its operational costs. With a disciplined strategy, the company has achieved substantial profitability improvements.

Now entering a new chapter of disciplined, sustainable growth, Blitz plans to use its secured funding to accelerate expansion across Indonesia. With a sharper focus on efficiency, quality clients, and scalable operations, the company is aligning its resources to drive stronger unit economics and long-term value. This renewed strategy positions Blitz to move confidently toward profitability while continuing to deliver impact at scale. 

“The initial growth phase is behind us. Now, our focus is disciplined scaling. That means maximizing what works and discontinuing what doesn’t,” said Saivya Chauhan, Founder and CEO of Blitz. “This funding reflects confidence in our proven model and positions us to secure capital aligned with our long-term objectives,” added William So, Co-Founder and CFO of Blitz. 

“Blitz is solving a fundamental challenge for businesses in Southeast Asia: how to scale logistics rapidly without the overhead of owning infrastructure,” said Victor Chua, Vynn Capital’s Founding & Managing Partner. “Their model empowers brands to meet growing delivery expectations with speed, reliability, and sustainability. As we double down on our mobility and supply chain thesis, Blitz stands out as a commercially disciplined operator ready to reshape how businesses move goods across the region.”

Blitz’s Key Milestones in 2024 and 2025: Partnerships and Innovation 

  • Forbes Under 30: Blitz and CEO Saivya Chauhan named to Forbes 30 Under 30 List for Consumer & Enterprise Technology (Class of 2025).
  • NVIDIA Inception Partnership: Selected for NVIDIA’s Inception program, gaining advanced AI tools for routing, driver performance analytics, and SLA forecasting.
  • Grab Ventures Collaboration: Integrated Blitz’s EV fleet with Grab’s platform, enhancing sustainable last-mile delivery.
  • Operational Scale: Completed over 14 million deliveries, deployed over 1,000 EV bikes, and logged 220 million electric kilometres.
  • Market Expansion: Grew operational footprint to 60 cities, becoming Indonesia’s largest EV logistics provider. 

Market Size  

Courier, Express, and Parcel Market Size in Indonesia is estimated to be valued at US$7.86 billion in 2025, with a projected compound annual growth rate (CAGR) of 7.24%. By the end of the decade, the market is expected to reach US$11.15 billion[1], demonstrating significant growth driven by the increasing number of small and medium-sized enterprises (SMEs) and the rapid expansion of e-commerce in the country. 

About Vynn Capital 

Vynn Capital is an industry-focused early-stage venture capital firm investing in transformative companies across mobility, travel, and supply chains. With deep local networks and a partnership-driven approach, Vynn Capital supports founders through capital and strategic collaboration. Learn more at vynncapital.com.

About Blitz 

Blitz is Indonesia’s largest and leading EV logistics enabler, providing white-labelled, instant, and same-day deliveries powered by electric vehicles and proprietary technology. Visit rideblitz.com

Reference: 

  1. Mordor Intelligence. (2025, March 18). Mordor Intelligence. Global Information, Inc. (GII) – Premium market research reports. https://www.mordorintelligence.com/industry-reports/indonesia-courier-express-and-parcel-cep-market

 

PPA Tour Asia is bringing Back-to-Back Cups to Malaysia and Vietnam

SINGAPORE, Aug. 25, 2025 /PRNewswire/ — Two straight weeks of pure pickleball action is on the horizon, with PPA Tour Asia bringing back-to-back Cups to the region. Malaysia and Vietnam are set to host the biggest names and most hardcore fans, as pickleball continues to take over the continent’s courts. 

Double Cups Set Stage For South East Asia Pickleball Showdown
Double Cups Set Stage For South East Asia Pickleball Showdown

The action starts with the Malaysia Cup (September 24-28, 2025) at 9Pickle Setia Alam and Setia City Convention Centre in Kuala Lumpur, before moving straight into the Vietnam Cup (September 30 – October 4, 2025) at Tien Son Sports Arena and Tuyen Son Sports Complex in Da Nang. With US$150,000 pro prize pool at each stop and world-class venues waiting, the events have already locked in some serious star power.  

Headlining the action will be Ben Johns. With over 150 PPA Tour titles made in the USA, Johns is now bringing the GOAT experience right to Asia’s door.

Joining the hunt for gold is No.1 Men’s Singles superstar Federico Staksrud. The Argentinian powerhouse will be jetting across the Pacific to compete in the heart of Asian pickleball. Royalty will be taking the spotlight with doubles queen Anna Bright bringing the heat to Malaysia.

The blockbuster lineup continues with Tyson McGuffin, Tyra Hurricane Black, Christian Alshon, Zane Navratil, Zoey Chao Yi Wang, Kaitlyn Christian, Alix Truong and even more fan favorites and local heroes ready to post up with their paddles.

“We are excited to bring our inaugural PPA Tour Asia Cups to Malaysia and Vietnam in collaboration with our hosts Bold D Court and Manage, and Americas & Asia Connect Company respectively. Attracting the globe’s best pickleball athletes to the region, fans will be able to watch players from the region challenge the best of the best as the sport continues to rapidly grow across Asia,” said Kimberly Koh, UPA Asia Managing Director.

Amateur action will be a key part of both tournaments. Players of all ages and divisions will compete alongside the pros, with gold medals and bragging rights up for grabs across both weeks.

Get ready for a journey through the heart of Asian pickleball. Stay tuned for more updates on ticketing, player registration and fan experiences.

About PPA Tour Asia:

PPA Tour Asia features a three-tier tournament structure – Slam, Cup and Open events – ensuring all regions and levels of competition experience the premier pickleball tour. Points earned at these events count towards the PPA Tour Asia Rankings, as players chase the prestigious No.1 crown – the ultimate recognition for dominance in Asian professional pickleball.

About UPA Asia:

UPA Asia, operating the PPA Tour Asia, is the premier professional and amateur pickleball tour in Asia, dedicated to expanding the sport’s highest level across the region. We focus on developing professional athletes through world-class events, elite training programs, and professional pathways while engaging new fans and growing participation. By forging strategic partnerships and delivering exceptional tournament experiences, we’re positioning pickleball as a leading sport in Asia.
PPA Tour Asia: Instagram | Facebook | YouTube | LinkedIn |

Tavo Unveils the Shell™ – A Pet’s Elevated Sanctuary of Comfort and Style

Thoughtfully engineered with a motion-locking sway, elevated design, and naturally flame-resistant fabrics, the Tavo Shell blends safety, style, and serenity into one elegant, pet-ready sanctuary.


SINGAPORE – Media OutReach Newswire – 25 August 2025 – Tavo Pets, the pet protection brand from the creators of the premium child car seat brand Nuna Baby, returns with another design-forward essential. Introducing the Tavo Shell, a revolutionary pet bed and swaying lounger that is set to redefine pet comfort, offering a dedicated safe haven that seamlessly integrates into the modern home. Hot on the heels of its Maeve™ 3-in-1 Pet Travel System, Tavo continues its mission to bring design and wellbeing together for pets and their people.

Tavo Shell™
Tavo Shell™

“At Tavo, we hold an uncompromising belief that life is better when it’s shared between people and their pets,” said Helen Johnson, Marketing Director at Tavo Pets and Nuna Baby. “Drawing upon decades of Nuna’s safety expertise and purposeful design, we apply the same rigorous standards to every pet essential we create. The Shell is a natural extension of that philosophy, designed not only to look beautiful in your home, but to deliver the same level of care, comfort, and protection we’ve long reserved for our little ones.”

Meet The Shell: A Sanctuary of Style and Snuggles

The Tavo Shell is designed to elevate your pet’s comfort—literally. Crafted with a unique shell-inspired design that gently sways like ocean waves, it cradles your pet in unparalleled comfort, offering a serene retreat. The raised platform with cloud-like cushioning lifts your pet away from dust and drafts, bringing them closer to you for restful connections and a better view of their surroundings. Equal parts modern art and pet paradise, the Shell is the perfect mix of style and snuggle, providing a throne worthy of your pet’s loyalty while enhancing your home’s aesthetic.

Thoughtful Innovation for Pet Well-Being and Owner Peace of Mind

The Tavo Shell stands apart with its meticulously engineered features, prioritising both pet safety and owner convenience:

Three Recline Positions: Designed to help your pet find the position that’s just right for ultimate relaxation and support.

Soothing Side-to-Side Motion: A gentle push initiates a calming, unassisted swaying motion that lasts for up to two minutes. Crucially, the Shell operates without cords, batteries, or noises, eliminating potential hazards such as entanglement, accidental ingestion of materials, or startling sounds that can cause anxiety in pets. This thoughtful design ensures a truly safe, calm, and uninterrupted sanctuary.

Motion Lock Feature: For moments when stillness is preferred, the Shell easily locks into a stationary position, providing versatility and stability.

Dedicated Comfort Zone: Its unique shell-like shape cradles pets, making them feel safe and secure in their personal haven.

Elevated Downtime: The raised design offers a perfect perching platform for cats or for dogs who enjoy a higher vantage point.

Soft, Machine-Washable Fleece: The removable, ultra-soft fleece seat cover easily zips off and is machine washable, ensuring effortless hygiene and long-term freshness.

Strong Frame & Base: Built with a strong interior aluminum frame and a curved base, the Shell provides exceptional stability. This robust construction ensures the lounger maintains its elegant form and supportive structure even with energetic pets jumping on and off, preventing it from becoming out of shape after use. It is also simple to assemble and disassemble, with the seat detaching from the base for convenient storage and transport.

Naturally Flame-Resistant Fabrics: In line with Tavo’s commitment to safety, the Shell’s fabrics are naturally flame-resistant and free of harmful fire-retardant chemicals, making them safer for your pet and providing owners with added peace of mind.

Unlike conventional pet lounging solutions that can present safety concerns or behavioral issues, the Tavo Shell is engineered to mitigate these risks. Its cord-free design and stable construction remove the dangers of chewing on wires or unstable structures. The gentle, unassisted sway fosters natural calming without the over-stimulation or anxiety sometimes associated with less thoughtfully designed pet swings.

The Tavo Shell Pet Bed and Swaying Lounger, suitable for pets up to 60kg and designed to fit beautifully into any home aesthetic, is available for a retail price of SGD $449, exclusively at https://tavopets.com/sg/shell-pet-bed?color=LATTE. It is also available on our official Shopee store for your convenience. Additional pet gear is expected to launch soon.
Hashtag: #TavoPets

The issuer is solely responsible for the content of this announcement.

About Tavo

Tavo is a revolutionary pet protection brand from the makers of Nuna Baby, designed to redefine the way we move through life with a pet. Tavo offers a broad lineup of pet travel gear, including crash-tested pet car seats with ISOFIX connectors that not only contain your pet but also anchor the entire carrier to the vehicle, delivering enhanced protection for everyone on board. Tavo also brings the journey home with adventure-ready stroller travel systems and design-forward essentials for everyday living. With its premium materials, timeless aesthetics, and rigorous safety testing, Tavo ensures your pet, and your people, travel and live safely, securely, calmly, and comfortably together. To learn more about Tavo, visit .

About Nuna

Nuna, the global brand with Dutch roots, has been focusing on creating smart, helpful and bold baby gear since 2007. First-hand experiences in parenthood show that practicality and beauty is the perfect balance when it comes to Nuna’s clever solutions that span across car seat, stroller, and in-home categories. Inspired by the clean lines and ingenuity of Dutch design, the collection is as easy, safe, and as flexible as new parents need it to be. With thoughtful design put into every detail, Nuna designs around your life.

Find out more at .

Saint Clare School Unveils AI-Backed Learning Management System for Special Education


SINGAPORE – Media OutReach Newswire – 25 August 2025 – Saint Clare School has launched a powerful new Learning Management System (LMS) designed to transform how teachers plan lessons and create Individualised Education Plans (IEPs) for students with special needs. Leveraging over 15 years of curriculum data and enhanced by generative AI, the platform streamlines planning, boosts teaching efficiency, and strengthens parent-teacher communication, paving the way for scalable, impactful special education both locally and abroad.

Students following AI-designed personalised education plans in class
Students following AI-designed personalised education plans in class

Empowering Teachers and Enhancing Collaboration

Developed in partnership with SOZCODE and guided by Saint Clare’s academic board, the LMS aims to reduce the special needs curriculum development time by 30–50%. Previously, teachers spent hours manually drafting IEPs and lesson plans. Now, they can input basic learning needs, such as “functional academics” or “social skills”, into the system and receive suggested learning goals and lesson ideas through an embedded SPED curriculum bank. Educators can then tailor these suggestions to fit the unique needs of each student.

“At the heart of it, the LMS provides more students with special needs to gain access to structured and validated curriculum especially in countries lacking in critical special needs education support and resources,” said Kelvin Ng, the co-founder of Saint Clare School.

Beyond curriculum support, the LMS features a “Single Child View,” consolidating each student’s class enrolment, IEPs, therapy records, attendance, and communication logs. Teachers, Heads of Department (HODs), and leadership teams can collaborate more efficiently, with each IEP and lesson plan undergoing a structured approval process. Built-in audit logs and timestamped actions ensure transparency and quality control at every step.

The Learning Management System also supports student progress tracking and custom analytics through platforms like Google Looker Studio. Educators can assess IEP effectiveness, identify trends in learning outcomes, and refine teaching approaches based on real data. Parental engagement is also tracked, ensuring timely communication and productive involvement in their child’s educational journey.

Scaling Special Education Across Southeast Asia

Saint Clare School’s long-term vision is to evolve the Learning Management System into a full-fledged SPED operating system, one that can be adopted by special education schools in Singapore and across the region. In late 2025 or early 2026, the system is slated to be piloted in two affiliated schools in Kuala Lumpur and Sabah.

This scalable solution is especially impactful for schools lacking structured special education frameworks. With its comprehensive curriculum bank and alignment to Singapore’s high standards, the platform empowers institutions to deliver credible, individualised learning support without starting from scratch.

With the successful rollout of this Learning Management System, Saint Clare School is leading the charge toward a more efficient, data-driven, and inclusive future for special education.
Hashtag: #SaintClareSchool #GenerativeAI #LearningManagementSystem


The issuer is solely responsible for the content of this announcement.

About Saint Clare School for Special Education

Established in 2007, Saint Clare School is a leading special needs education provider in Singapore, having supported over 2,000 students to date. The school focuses on helping students achieve learning, independent living, or work-related outcomes through individualised education plans tailored to their strengths and challenges. Saint Clare is EDUTRUST-certified by the Committee for Private Education, recognising its commitment to quality. The school has expanded regionally by licensing its curriculum and programmes to partners in Malaysia, with growing interest from Indonesia. To increase its impact, Saint Clare is digitising its curriculum through a scalable Learning Management System.

Harbour BioMed Appoints Yajie Li as Chief Medical Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 25, 2025 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.

In this role, Ms. Li will lead clinical development, regulatory strategy, and medical affairs for the company’s clinical-stage programs. She will also play a key role in evaluating early-stage assets based on unmet medical needs, clinical value, and scientific differentiation.

Ms. Li brings over a decade of experience in the pharmaceutical industry, with leadership roles in clinical development and regulatory affairs at multinational corporations and CROs including Merck, Johnson & Johnson and Parexel, as well as at Chinese biopharma companies such as GenSci, XuanZhu Biopharm, and Innovent. Prior to her industry career, she served for nine years as a Senior Medical Officer at the National Medical Products Administration of China (NMPA)/Center for Drug Evaluation (CDE), where she contributed to regulatory assessments across a broad range of therapeutic areas.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: “We are very pleased to welcome Yajie Li to our executive team. Her deep expertise in clinical development and regulatory science will further strengthen our capabilities as we advance our pipeline and grow into a therapeutically focused biopharma company. We look forward to her leadership in delivering transformative medicines to patients around the world.”

Yajie Li, Chief Medical Officer of Harbour BioMed, added: “It is a great honor to join Harbour BioMed as Chief Medical Officer at this pivotal stage of its growth. The company’s cutting-edge antibody technology platform and global R&D strategy is well positioned to deliver innovative therapies in areas of high unmet need. I look forward to working with the team to accelerate clinical development, enhance regulatory alignment, and bring meaningful treatments to patients worldwide.”

Ms. Li holds a master’s degree in Rheumatology and Immunology from Peking Union Medical College.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

Longbridge Group Collaborates with Cboe to Expand Global Index Offering, Enhancing Investor Access to Key Market Data

SINGAPORE, Aug. 25, 2025 /PRNewswire/ — Longbridge Group, a leading financial technology innovator, today announced that it has added the Cboe Global Indices Feed to its data coverage, empowering its clients with advanced tools to navigate dynamic markets and strengthening Longbridge’s position as a gateway to institutional grade insights for retail and professional investors alike.

Longbridge × Cboe | Strategic partnership announced in Singapore
Longbridge × Cboe | Strategic partnership announced in Singapore

The Cboe Global Indices Feed delivers real-time index values to market participants including globally recognized indices such as the S&P 500 Index (SPX®) and the Cboe Volatility Index (VIX®). As part of the agreement, Longbridge has launched real-time VIX Index data—a critical benchmark for measuring near term U.S. equity market volatility. The VIX Index is designed to reflect investor sentiment and serves as a powerful tool for risk assessment, hedging strategies, and opportunistic trading.

Adam Inzirillo, Global Head of Cboe Data Vantage, said: “We’re proud to be working with Longbridge to broaden access to the Cboe Global Indices Feed, which includes data for industry leading indices such as the SPX and VIX, for a wider community of retail investors. We believe that high-quality, reliable data is a cornerstone of informed decision-making and effective trading strategies, and this collaboration reinforces Cboe’s ongoing commitment to making premium market data more accessible to individual investors around the world.”

Zhong Hua, Head of Technology Business at Longbridge Group, stated: “We are excited to integrate the Cboe Global Indices Feed into our platform to deliver richer market data services to our clients. With this collaboration, we have officially launched real-time VIX index quotes, and we look forward to offering more high quality index data from Cboe in the near future. Indices like the VIX provide valuable insight into market sentiment and can help investors quickly adjust their strategies. This is a key milestone in Longbridge Group’s mission to build a world class global trading infrastructure and enhance our financial services ecosystem.”

Longbridge Securities, the group’s brokerage arm, now provides free real-time quotes for critical indices including the VIX and SPX indices, giving all clients instant access to professional-grade volatility and benchmark data. The platform will soon expand its offerings to include the Cboe Global Indices Feed and enhanced risk management tools, demonstrating Longbridge’s commitment to democratize professional trading tools and empower investors to trade with more confidence.

About Longbridge Group

Longbridge Group is a leading fintech company with three core business segments: Securities, Technology, and Community. Its flagship platform, Longbridge (longbridge.com), is an AI-driven online brokerage offering global investors seamless trading experiences. Longbridge Whale (longbridgewhale.com) provides comprehensive digital trading and wealth management solutions for financial institutions and high-net-worth individuals. LongPort (longportapp.com) is a global investor community platform offering market data, advanced tools, and AI powered investment support through PortAI.

Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Aug. 25, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimmune, ophthalmology and other major therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a global Phase 3 clinical trial (MarsLight-11) of IBI363 in immunotherapy(IO)-resistant squamous non-small cell lung cancer (NSCLC). IBI363 is Innovent’s self-discovered novel PD-1/IL-2α-bias bispecific antibody fusion protein. The upcoming study will be the first global Phase 3 trial of IBI363 and represents a significant milestone in advancing a first-in-class, dual-immune activation immunotherapy for this large patient population. Besides, the pivotal trial of IBI363 head-to-head against pembrolizumab (Keytruda®) in the treatment of melanoma is underway in China.

IBI363 as a Next-generation IO therapy Set for First Global Phase 3 Lung Cancer Trial

This IND clearance follows recent positive feedback from the U.S. FDA at the End-of-Phase 2 (EOP2) meeting. Major alignments of the Phase 3 program were reached regarding the dose selection, study design, and other critical considerations. Innovent has also received IND approval from China’s National Medical Products Administration (NMPA) for this program. In parallel, Innovent has initiated communications and submissions to other major Health authorities. IBI363 has also received Fast Track Designation (FTD) from the FDA and Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) in China for this indication.

The multi-regional, randomized, controlled Phase 3 trial will enroll approximately 600 patients globally including China, U.S., Canada, EU, UK, and Japan, etc. The study will evaluate the efficacy and safety of IBI363 3 mg/kg monotherapy compared with docetaxel in patients with unresectable, locally advanced or metastatic squamous NSCLC who have experienced disease progression following platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. The primary endpoint is overall survival.

IBI363’s Breakthrough Data Validates its Dual-immune Activation Mechanism, Stepwise Development in Multiple Tumor Types

At ASCO 2025, Phase 1b/2 results demonstrated meaningful and durable clinical activity in areas of high unmet need, including IO-resistant lung cancer, traditionally “cold tumors” such as acral and mucosal melanoma, and microsatellite stable (MSS) colorectal cancer.

These promising data position IBI363 as a potential first-in-class dual-immune activation therapy with broad applicability across difficult-to-treat cancers. Innovent is rapidly progressing IBI363 into registrational studies, with a pivotal program in melanoma already ongoing, a global Phase 3 trial in squamous NSCLC expected to start shortly, and a registration strategy in colorectal cancer in planning.

In parallel, multiple Phase 1b/2 trials are evaluating IBI363 both as monotherapy and in combinations in first-line NSCLC, first-line CRC, and additional tumor types, including platinum-resistant ovarian cancer (PROC), EGFR+ NSCLC, and neoadjuvant therapy for non-squamous NSCLC. This comprehensive development strategy is designed to maximize the value of IBI363 and expand its potential to address multiple large global oncology markets and improve patient outcomes.

Roy S. Herbst, MD, PhD, Deputy Director and Chief of Medical Oncology and Hematology for Yale Cancer Center and Smilow Cancer Hospital, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale School of Medicine, shared, “Lung cancer remains the most prevalent malignant tumor worldwide, with particularly high incidence and mortality rates globally. Non-small cell lung cancer constitutes the majority of these cases. Although immunotherapy has significantly improved survival outcomes for some patients, those who do not respond to such treatments and lack driver gene mutations have limited therapeutic options, underscoring the urgent need for enhanced clinical interventions.

Clinical research of the PD-1/IL-2α-biased bispecific molecule IBI363 has revealed encouraging findings.  Preliminary trials have demonstrated that IBI363 not only induces tumor remission in a subset of patients but also achieves disease stability in the majority of patients, indicating durable anti-tumor activity. In comparison to traditional chemotherapy, IBI363 appears to offer potential advantages in both objective response rate (ORR) and progression-free survival (PFS), providing new hope for patients diagnosed with lung cancer.”

Professor Shun Lu from the Oncology Department of Shanghai Chest Hospital, stated: “As a first-in-class PD-1/IL-2α-biased bispecific antibody fusion protein, IBI363 acts by simultaneously blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI363 is engineered to retain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2. This dual mechanism targets and activates tumor-specific T cells co-expressing PD-1 and IL-2α, enabling more precise and effective stimulation of this T-cell subpopulation. IBI363 has demonstrated robust antitumor activity across multiple tumor models and has shown remarkable efficacy in IO-resistant, PD-L1 low expression, and cold tumor settings.

The promising data associated with IBI363 offers a novel treatment avenue for patients with non-small cell lung cancer who have not responded to immunotherapy. As research progresses, this innovative therapy holds the potential to bridge clinical gaps and provide the possibility of long-term survival for a greater number of patients.”

Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent Biologics, said, “Today’s IND clearance marks a significant milestone as we initiate the first global Phase 3 trial of our next-generation IO therapy, IBI363 (PD-1/IL-2α-bias). If successful, this trial could bring a potentially transformative treatment to patients with squamous NSCLC worldwide, who currently have limited options after checkpoint inhibitor therapy. Concurrently, we are exploring IBI363 in a broad global clinical program and look forward to more data and continued development in the future.

This achievement also signifies a milestone for Innovent’s global innovation strategy, rooted in our mission to ’empower patients worldwide with affordable, high-quality biopharmaceuticals’ and our vision to ‘build a global premier biopharmaceutical leader.’ Having developed a highly competitive pipeline aligned with our globalization strategy, we have prioritized the global R&D of our assets, alongside expanding our international team and footprint to accelerate the development and access of innovative therapies worldwide.

In addition to IBI363, Innovent is advancing a broader pipeline for global development, including next-generation ADC programs such as bispecific and dual-payload ADCs. We believe our robust pipeline and ongoing R&D efforts will continue to expand our impact in oncology on a global scale.”

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

(1)Innovent does not recommend the use of any unapproved drug (s)/indication (s).

(2)Ramucirumab (Cyramza),Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent Biologics, Inc. (“Innovent” or “Company”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.